Relmada Therapeutics (RLMD) to Release Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Relmada Therapeutics to post earnings of ($0.04) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.05). On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Stock Performance

Shares of NASDAQ:RLMD opened at $2.45 on Thursday. The stock has a market capitalization of $81.32 million, a price-to-earnings ratio of -1.10 and a beta of 0.91. Relmada Therapeutics has a 1-year low of $0.24 and a 1-year high of $3.67. The company’s fifty day moving average is $1.72 and its two-hundred day moving average is $0.98.

Hedge Funds Weigh In On Relmada Therapeutics

Several large investors have recently made changes to their positions in the business. Corient Private Wealth LLC bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at about $120,000. LMR Partners LLP bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at about $69,000. Marshall Wace LLP bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at about $93,000. Finally, XTX Topco Ltd bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at about $28,000. Institutional investors own 45.24% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relmada Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Relmada Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $1.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.